Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.
Dr. Geoffrey Liu
Advertisement
Dr. Geoffrey Liu is a senior scientist at Princess Margaret Cancer Centre and a professor in the Epidemiology Division at Dalla Lana School of Public Health of the University of Toronto.
Articles by Dr. Geoffrey Liu
Dr. Geoffrey Liu discussed findings from the phase 2 TRUST-II clinical trial evaluating Ibtrozi (taletrectinib) among patients with ROS1-positive non-small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
2
Fertility Preservation During Breast Cancer: ‘I Would Do It All Again’
3
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
4
What Are My Options for Liver Cancer Treatment?
5
